These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 2655680)

  • 41. Pharmacokinetics and dose linearity testing of methylprednisolone phosphate.
    Möllmann H; Rohdewald P; Barth J; Verho M; Derendorf H
    Biopharm Drug Dispos; 1989; 10(5):453-64. PubMed ID: 2804250
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High dose oral methylprednisolone in patients with rheumatoid arthritis: pharmacokinetics and clinical response.
    Hayball PJ; Cosh DG; Ahern MJ; Schultz DW; Roberts-Thomson PJ
    Eur J Clin Pharmacol; 1992; 42(1):85-8. PubMed ID: 1541321
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis.
    Morrow SA; Stoian CA; Dmitrovic J; Chan SC; Metz LM
    Neurology; 2004 Sep; 63(6):1079-80. PubMed ID: 15452302
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
    Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
    Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects.
    Kong AN; Ludwig EA; Slaughter RL; DiStefano PM; DeMasi J; Middleton E; Jusko WJ
    Clin Pharmacol Ther; 1989 Dec; 46(6):616-28. PubMed ID: 2689044
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of route of administration on the pharmacokinetics of methylprednisolone.
    Antal EJ; Wright CE; Gillespie WR; Albert KS
    J Pharmacokinet Biopharm; 1983 Dec; 11(6):561-76. PubMed ID: 6678310
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics of methylprednisolone during acute renal allograft rejection.
    Tornatore KM; Walshe JJ; Reed K; Venuto RC
    Clin Transplant; 1995 Apr; 9(2):74-8. PubMed ID: 7599405
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Simultaneous analysis of methylprednisolone, methylprednisolone succinate, and endogenous corticosterone in rat plasma.
    Mehvar R; Dann RO; Hoganson DA
    J Pharm Biomed Anal; 2000 Jul; 22(6):1015-22. PubMed ID: 10857570
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics after Periocular Methylprednisolone Sodium Succinate Injection in Rabbit Eyes.
    Lu HY; Wang RQ; Li X; Li X
    Evid Based Complement Alternat Med; 2020; 2020():8120398. PubMed ID: 32190090
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-performance liquid chromatographic determination of hydrocortisone and methylprednisolone and their hemisuccinate esters in human serum.
    Smith MD
    J Chromatogr; 1979 Oct; 164(2):129-37. PubMed ID: 541404
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of two ester prodrugs of methylprednisolone on early neurologic recovery in a murine closed head injury model.
    Hall ED; Yonkers PA
    J Neurotrauma; 1989; 6(3):163-8. PubMed ID: 2681792
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stability of methylprednisolone sodium succinate in 5% dextrose and 0.9% sodium chloride injections.
    Pyter RA; Hsu LC; Buddenhagen JD
    Am J Hosp Pharm; 1983 Aug; 40(8):1329-33. PubMed ID: 6351604
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: dose-dependent pharmacokinetics in rats.
    Zhang X; Mehvar R
    Int J Pharm; 2001 Oct; 229(1-2):173-82. PubMed ID: 11604270
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics and bioavailability of benperidol in schizophrenic patients after intravenous and two different kinds of oral application.
    Seiler W; Wetzel H; Hillert A; Schöllnhammer G; Langer M; Barlage U; Hiemke C
    Psychopharmacology (Berl); 1994 Dec; 116(4):457-63. PubMed ID: 7701049
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Urinary profile of methylprednisolone and its metabolites after oral and topical administrations.
    Matabosch X; Pozo OJ; Monfort N; Pérez-Mañá C; Farré M; Marcos J; Segura J; Ventura R
    J Steroid Biochem Mol Biol; 2013 Nov; 138():214-21. PubMed ID: 23792784
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: immunosuppressive effects after in vivo administration to rats.
    Mehvar R; Hoganson DA
    Pharm Res; 2000 Nov; 17(11):1402-7. PubMed ID: 11205734
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rapid method for the measurement of methylprednisolone and its hemisuccinate in plasma and urine following "pulse therapy" by high-performance liquid chromatography.
    Lawson GJ
    J Chromatogr; 1985 Aug; 342(2):251-60. PubMed ID: 3902861
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of intravenous and oral prednisolone.
    Al-Habet S; Rogers HJ
    Br J Clin Pharmacol; 1980 Nov; 10(5):503-8. PubMed ID: 7437263
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics of methylprednisolone in cat plasma and spinal cord following a single intravenous dose of the sodium succinate ester.
    Braughler JM; Hall ED
    Drug Metab Dispos; 1982; 10(5):551-2. PubMed ID: 6128209
    [No Abstract]   [Full Text] [Related]  

  • 60. Methylprednisolone as an intervention following myocardial infarction. The Solu-Medrol Sterile Powder AMI Studies Group.
    J Int Med Res; 1986; 14 Suppl 1():1-10. PubMed ID: 2875003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.